Study	Reason for exclusion
Adler 1999	Allocation: randomised. Participants: people with non‐organic psychosis. Interventions: vitamin E versus placebo.
Akhondzadeh 2005	Allocation: randomised. Participants: people with chronic schizophrenia. Interventions: risperidone plus lamotrigine versus risperidone plus placebo.
Akhondzadeh 2007	Allocation: randomised. Participants: people with chronic schizophrenia. Interventions: risperidone plus celecoxib versus risperidone plus placebo.
Anwunah 1999	Allocation: randomised. Participants: people with schizotypal personality disorder.
Ayd 2001	Allocation: randomised. Participants: people with schizotypal personality disorder.
Azorin 2002	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus sertindole.
Azorin 2006	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus sertindole.
Bai 2005	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus other atypicals (no placebo arm).
Baker 2012	Allocation: not RCT but pooled data from RCTs.
Basson 2001	Allocation: randomised. Participants: people with schizophrenia. Intervention: olanzapine versus haloperidol versus risperidone.
Beasley 1996	Allocation: randomised. Participants: people with schizophrenia. Intervention: olanzapine versus placebo versus haloperidol.
Bondolfi 1998	Allocation: randomised. Participants: people with resistant schizophrenia. Intervention: clozapine versus risperidone.
Borison 1992a	Allocation: randomised. Participants: people with chronic schizophrenia. Intervention: risperidone versus haloperidol.
Boyer 1995	Allocation: randomised. Participants: people with negative schizophrenia. Intervention: amisulpride versus placebo.
Brecher 1998	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus olanzapine.
Cada 2004	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone long‐acting injection versus placebo.
Carson 2002	Allocation: randomised. Participants: people with schizophrenia. Intervention: aripiprazole versus haloperidol versus placebo.
Casey 2003	Allocation: randomised. Participants: people with schizophrenia. Intervention: aripiprazole versus placebo.
Castle 2015	Allocation: not RCT but pooled data from RCTs.
Chan 2007	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus aripiprazole.
Chue 2002	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone long‐acting injection versus olanzapine.
Ciliberto 2005	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone long‐acting injection versus placebo.
Citrome 2004	Allocation: randomised. Participants: people with schizophrenia. Intervention: antipsychotic monotherapy versus antipsychotic plus valproate.
Claus 1992	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus haloperidol.
Conley 1998	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus olanzapine.
Cooper 1997	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus olanzapine versus quetiapine.
Cornblatt 2002	Allocation: randomised. Participants: people with schizophrenia. Intervention: aripiprazole versus olanzapine.
Crawford 1997	Allocation: randomised. Participants: people with schizophrenia. Intervention: olanzapine versus haloperidol versus placebo.
Csernansky 1999	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus haloperidol.
David 2000	Allocation: not randomised.
Davis 2001	Allocation: not randomised.
Dossenbach 1997	Allocation: randomised. Participants: people with schizophrenia. Interventions: olanzapine versus fluphenazine.
Dubitsky 2002	Allocation: randomised. Participants: people with schizophrenia. Intervention: aripiprazole versus risperidone.
Edgell 2000	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus olanzapine.
Fleming 2007a	Allocation: randomised. Participants: people with schizophrenia. Intervention: asenapine versus risperidone versus placebo.
Friedman 2000	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus haloperidol.
Gismondi 2004	Allocation: randomised. Participants: people with schizophrenia. Interventions: aripiprazole versus perphenazine.
Gregor 2000	Allocation: randomised. Participants: people with schizophrenia. Interventions: olanzapine versus haloperidol.
Harvey 2001	Allocation: randomised. Participants: people with schizophrenia and schizoaffective disorder. Interventions: risperidone versus olanzapine.
Hwang 2003	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus amisulpride.
Hwang 2005	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus aripiprazole.
Kane 2005	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone, sertindole, and aripiprazole.
Kinon 1998	Allocation: randomised. Participants: people with schizophrenia. Interventions: olanzapine versus haloperidol.
Kinon 2015	Allocation: not RCT, but pooled data from five RCTs.
Lauriello 2005	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone long‐acting injection versus placebo.
Lemmens 1994	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus zuclopenthixol dihydrochloride.
Lieberman 2005	Allocation: randomised. Participants: people with schizophrenia. Interventions: olanzapine versus haloperidol.
Lindstrom 1994	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus haloperidol.
Loo 1997	Allocation: randomised. Participants: people with deficit schizophrenia. Interventions: amisulpride versus placebo.
Lopez 1996	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus haloperidol.
Lopez‐Ibor 1992	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus haloperidol.
Luo 2011	Allocation: randomised. Participants: people with schizophrenia. Intervention: paliperidone versus olanzapine versus placebo.
Marder 1991	Allocation: not RCT, but pooled data from two RCTs.
McClellan 2009	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus olanzapine or molindone.
McClure 2009	Allocation: randomised. Patients: Schizotypal personality disorder.
McKenna 2004	Allocation: randomised. Participants: people with refractory schizophrenia. Intervention: clozapine versus clozapine plus risperidone.
Nasrallah 2004a	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone long‐acting injection versus placebo.
NCT 02109562	Allocation: randomised. Participants: people with schizophrenia. Interventions: resperidone injections versus placebo.
NCT00034892	Allocation: randomised. Participants: people with schizophrenia, schizophreniform disorder, and schizoaffective disorder. Interventions: risperidone versus quetiapine versus olanzapine.
NCT00088075	Allocation: randomised. Participants: adolescents with schizophrenia.
NCT00202007	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus aripiprazole.
NCT00249119	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone long‐acting injection versus placebo.
NCT00253136	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus haloperidol.
NCT00305474	Allocation: randomised. Participants: non‐psychotic relatives of people with schizophrenia.
Peuskens 1995	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus haloperidol.
Peuskens 2001	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus amisulpride.
Peuskens 2001a	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus amisulpride plus haloperidol.
Pikalov 2012	Allocation: not RCT, but pooled data from seven RCTs.
Rabinowitz 2001	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus haloperidol.
Rein 2002	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus amisulpride.
Revicki 1996	Allocation: randomised. Participants: people with schizophrenia. Interventions: olanzapine versus haloperidol.
Riedel 2003	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone plus celecoxib versus risperidone plus placebo.
Schmechtig 2010	Allocation: randomised. Participants: health volunteers.
Siever 2002	Allocation: randomised. Participants: people with schizotypal personality disorder.
Tollefson 1996	Allocation: randomised. Participants: people with schizophrenia. Intervention: olanzapine versus risperidone.
Tran 1997	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus olanzapine.
Tsai 2004	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone plus sarcosine versus risperidone plus placebo.
Tsai 2006	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone plus D‐alanine versus risperidone plus placebo.
Urioste 2004	Allocation: randomised. Participants: people with schizophrenia and schizoaffective disorder. Intervention: risperidone long‐acting injection versus placebo.
Wang 2003	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone plus valproate versus risperidone plus placebo.
Weickert 2003	Allocation: randomised. Participants: people with schizophrenia. Intervention: antipsychotic drugs (risperidone, olanzapine, quetiapine) versus placebo.
Weiden 2005	Allocation: randomised. Participants: schizophrenia with obesity. Intervention: sibutramin vs placebo
Wirshing 1995	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus haloperidol.
Yamawaki 1996	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus clocapramine (an atypical antipsychotic of the imidobenzyl class).
Zhang 2002	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone plus antioxidants versus risperidone plus placebo.
Zhong 2006	Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone plus buflomedil versus risperidone plus placebo.